The dedicated women health’s firm, Theramex has recently announced that they have acquired the Femarelle® product license to treat menopause symptoms. The Femarelle tables will be available in different markets from the second quarter of the next year.
“Our main objective is to meet women’s health needs around the world, Not only their current needs but future ones too in order to improve their lives. With Femarelle®, we are adding to our portfolio an alternative for women with untreated menopause who are reluctant to use hormone therapy”Robert Stewart, Theramex chief executive
Se-cure Pharmaceuticals Ltd. developed the product and now it is the one who came to an arrangement with the corporation to commercialize the product. Femarelle is a non-hormonal medication that helps people balance their estrogen levels from perimenopause to post-menopause. It relieves the symptoms and conditions derived from estrogen loss with the onset of menopause.
“We are very excited about this collaboration with Theramex. Together we will provide women with more menopausal symptom treatment options”Esti Grunbaum, Vice President BD & Marketing at Se-cure Pharmaceuticals Ltd
In a survey of 4,000-plus women from different countries, hot flushes and night sweats were the main symptoms in all countries. Femarelle was found to considerably reduce menopausal symptoms. after the first two weeks of treatment and remained after four weeks of treatment.
“We offer a non-hormonal option to healthcare professionals, backed by scientific studies. This allows us to cover an unmet need for these women who will now be heard, understood, and have access to a treatment that will provide them with greater adherence and therefore a better quality of life”Jose Naranjo, Theramex Vice President Marketing
With this move, Theramex keeps proving its dedication to providing women with an effective and safe alternative to menopause hormone therapy.